Apitoria Pharma gets Form 483 with 10 observations from USFDA

The observations are of procedural in nature and will be responded to within the stipulated time

Piramal Pharma Solutions announces US$ 80 million expansion plan for Sterile Injectables facility in Kentucky

Briefs: Lupin, Alembic Pharmaceuticals and Piramal Pharma

Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations

Torrent Pharmaceuticals refutes claims of Shelcal 500 allegedly failing CDSCO quality test

The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious

Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress

The company will also share results in two additional posters for deuruxolitinib

Briefs: Krsnaa Diagnostics and Anuh Pharma

Krsnaa Diagnostics receives LoI from RINPAS for radiology services

Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 40 mg as additional formulation in Japan

The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg

Vaishali Pharma plans M&A route to drive growth

Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies

AstraZeneca Pharma India to launch Tremelimumab

Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma

Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations